CNS, CAR T cell, EGFR-positive
Showing 1 - 25 of >10,000
CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)
Active, not recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- EGFR806-specific chimeric antigen receptor (CAR) T cell
-
Seattle, WashingtonSeattle Children's Hospital
Jan 18, 2023
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult Trial in Seattle (SC-CAR4BRAIN)
Not yet recruiting
- Diffuse Intrinsic Pontine Glioma
- +4 more
- SC-CAR4BRAIN
-
Seattle, WashingtonSeattle Children's Hospital
Mar 3, 2023
CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (HER2-specific chimeric antigen receptor (CAR) T cell)
Recruiting
- Central Nervous System Tumor, Pediatric
- +8 more
- HER2-specific chimeric antigen receptor (CAR) T cell
-
Seattle, WashingtonSeattle Children's Hospital
Dec 14, 2022
CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)
Recruiting
- CD70-positive Advanced Urologic Neoplasms
- Anti-CD70 CAR-T cells
-
Shanghai, Shanghai, ChinaChanghai Hospital
Aug 11, 2023
Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)
Recruiting
- Lymphoma
- CD70-targeting CAR-T cells
-
Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, ChinaChina
Jul 9, 2023
Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)
Recruiting
- Solid Tumor, Adult
- CD70-targeting CAR-T cells
-
Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, ChinaChina
Jul 8, 2023
Solid Tumor, Adult, EGFR Overexpression Trial in Beijing (TGFßR-KO CAR-EGFR T Cells)
Recruiting
- Solid Tumor, Adult
- EGFR Overexpression
- TGFβR-KO CAR-EGFR T Cells
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Mar 25, 2022
Mesothelin-positive Advanced Malignant Solid Tumors Trial in Hangzhou (UCLM802 Cell Injection (Anti-mesothelin CAR-T cells))
Recruiting
- Mesothelin-positive Advanced Malignant Solid Tumors
- UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital Zhejiang University School of Medi
May 11, 2023
Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CAR-T Therapy
-
Hefei, Anhui, China
- +7 more
Jul 31, 2023
Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,
Recruiting
- Advanced or Metastatic Solid Tumors
- CD40 ligand expressing MSLN-CAR T cells
- +2 more
-
Beijing, Beijing, ChinaKaichao Feng
Jan 19, 2023
EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer Trial in Guangzhou
Recruiting
- EGFR/ B7H3-positive Advanced Lung Cancer
- EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
- EGFR/B7H3 CAR-T
-
Guangzhou, Guangdong, ChinaSecond Affiliated Hospital of Guangzhou Medical University
Apr 18, 2022
Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)
Not yet recruiting
- Mesothelin-positive Advanced Malignant Solid Tumors
- Anti-mesothelin CAR-T cells
- (no location specified)
Mar 13, 2023
Solid Tumor Trial (UCLM802 Cell Injection)
Not yet recruiting
- Solid Tumor
- UCLM802 Cell Injection
- (no location specified)
Mar 7, 2023
Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)
Recruiting
- Multiple Myeloma
- anti-BCMA CAR-T
-
Tianjin, Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
May 4, 2023
Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)
Recruiting
- Renal Cell Carcinoma
- +4 more
- CD70 CAR-T cells
-
Nanchang, Jiangxi, ChinaThe First Affiliated Hospital of Nanchang University
Aug 23, 2023
CNS Lymphoma Trial in Duarte (procedure, biological, drug)
Recruiting
- Central Nervous System Lymphoma
- Aspiration
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
Aug 29, 2022
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Xuzhou, Jiangsu, ChinaAffiliated hospital of Xuzhou medical college
Jun 7, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of University of Science and Techn
Jun 5, 2023
Nasopharyngeal Carcinoma Trial (PK Blood Collection, CAR, TCR)
Not yet recruiting
- Nasopharyngeal Carcinoma
- PK Blood Collection
- +2 more
- (no location specified)
Nov 1, 2022
Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023
Brain Tumor, Recurrent, Brain Tumor, Refractory Trial in Houston (HER2-specific T cells)
Recruiting
- Brain Tumor, Recurrent
- Brain Tumor, Refractory
- HER2-specific T cells
-
Houston, Texas
- +1 more
May 3, 2022